Last reviewed · How we verify
Hormone and radiation therapy — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Hormone and radiation therapy (Hormone and radiation therapy) — Spanish Oncology Genito-Urinary Group.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Hormone and radiation therapy TARGET | Hormone and radiation therapy | Spanish Oncology Genito-Urinary Group | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Hormone and radiation therapy CI watch — RSS
- Hormone and radiation therapy CI watch — Atom
- Hormone and radiation therapy CI watch — JSON
- Hormone and radiation therapy alone — RSS
Cite this brief
Drug Landscape (2026). Hormone and radiation therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/hormone-and-radiation-therapy. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab